Table 2.
Strain | Paternal exposure | Generation | Endpoint | Effect* | Ref. |
---|---|---|---|---|---|
Mice | |||||
ICR | X-rays (216 rad) | F1 | Lung tumors after treatment with urethane | Elevated | 29 |
SHR | X-rays (4.2 Gy) | F1, F2 | Skin tumors after treatment with phorbol 12-myristate 13-acetate | Elevated | 27 |
CBA/H | Injection with 239Pu | F1 | Lympho-hemopoietic malignancies after treatment with methylnitrosourea | Elevated | 30 |
DBA2 | Injection with 55Fe | F1 | Lympho-hemopoietic malignancies after treatment with methylnitrosourea | Elevated | 23 |
CBA | Injection with 239Pu | F1 | Pre-/postimplantation loss among offspring | Elevated | 18 |
HLG/Zte | X-rays (1 Gy) | F1 | Pre-/postimplantation loss and malformations among offspring | Elevated | 19 |
CBA/H | Neutrons (0.4 Gy) | F1 | Germ line mutation rate at two ESTR loci | Elevated | 3 |
C57BL/6 | X-rays (1–4 Gy) | F1 | Somatic mutation rate at lacI gene | Elevated | 26 |
C57BL/6J | X-rays (1 Gy) | F1 | Somatic reversions at pun locus | Elevated | 31 |
CD1 | γ-rays (1 Gy) | F1 | Proliferation of early embryonic cells in offspring | Decreased | 24 |
CD1 | γ-rays (1 Gy) | F1 | Fertilization rate for spermatozoa | Decreased | 25 |
CD1 | γ-rays (1 Gy) | F3 | Levels of p53 and p21waf1 | Elevated | 32 |
Rats | |||||
Sprague | Cyclophosphamide | F1 | Pre-/postimplantation loss and malformations among offspring | Elevated | 20 |
Swiss | X-rays (4.5 Gy) | F1 | Chromosome aberrations after treatment with x-rays or cyclophosphamide | Elevated | 28 |
Wistar | Cyclophosphamide | F1, F2 | Learning capacity | Decreased | 33 |
Compared with the offspring of nonexposed parents.